Quick answer
EHL BIO’s research team consists of over 85 specialists working with leading institutes to develop next-generation biologics. They utilize advanced cell culture technologies and state-of-the-art storage systems to enhance long-term health and quality of life according to EHL team evaluations.
Key takeaways
- A team of over 85 expert researchers focused on advancing regenerative medicine.
- Production capacity of up to 6,000 lots per year under strict GMP standards.
- High-purity Class 100 laboratory environment to ensure cell safety.
- Recognized with national research awards in Korea, including the 2025 Jang Young-shil Award.
The Heart of EHL BIO: A Leading Team of Research Experts
Founded in 2012, EHL BIO was built on a vision to lead biotechnology for the benefit of humanity. Our success is driven by the dedication of over 85 researchers and scientific personnel specializing in stem cell and immune cell development. Our team does not merely focus on laboratory experiments but aims for recovery goals and quality of life regarding neurological disorders, degenerative joint diseases, circulatory issues, and immune conditions.
Led by CEO MD Hong-gi Lee, the research team integrates medical and pharmaceutical technologies to enhance health. These efforts have established research collaborations with top universities in Korea, ensuring that the developed innovations remain at the forefront of the regenerative medicine industry.
GMP Production Standards and Class 100 Facilities
Cell safety and quality are the top priorities for EHL BIO’s research team. We operate research centers and production facilities certified by the Korean Ministry of Food and Drug Safety (MFDS) under GMP standards. Our Class 100 facilities ensure environmental control throughout every production stage.
Our team possesses the capability to manage up to 6,000 cell culture lots annually, equipped with advanced tools such as Biological Safety Cabinets (BSC), AHU systems with HEPA filters, and liquid nitrogen storage tanks for cryopreservation at -196°C. These ensure high cell viability and stable efficacy. Furthermore, we are the first in Korea to be licensed as a Human Cell Management Business under the Modern Regenerative Medicine Act.
Our research team is committed to making EHL BIO a leader in biotechnology for the benefit of humanity, ensuring recovery goals and better quality of life.
Innovation and Patents Driven by Research Excellence
EHL BIO’s team of 85+ researchers has produced numerous recognized studies and patents. A prime example is KDSTEM®, a urine-derived stem cell therapy aiming for recovery in chronic kidney disease, which received the 'IR52 Jang Young-shil' innovation award in 2025. Additionally, ADSTEM® for atopic dermatitis is currently entering Phase 3 clinical trials.
The research team has also patented specialized technologies, including the 15-PGDH Inhibitor for cardiovascular restoration and SVF cell separation kits that enhance precision. These achievements stem from extensive knowledge and experience gained through over 5,000 cell extraction procedures, enabling EHL BIO to achieve cell yields higher than average according to EHL team evaluations, while maintaining the effective Homing Effect for targeting tissues.
The Future of Regenerative Medicine and Collaboration Networks
EHL BIO continues to expand the boundaries of regenerative medicine. Our research team is currently investigating the efficacy of Exosomes and Conditioned Media for beauty and self-care applications, leading to the development of 'klosome'—a premium skin booster combining Klotho protein with cell technology.
We have established strategic partnerships in Korea and work with EHL Thailand, which provides a dedicated coordination team to ensure seamless care—from medical assessment to treatment planning in Korea and post-service follow-up—ensuring a sustainable quality of life for every client.
Frequently asked questions
What is EHL BIO’s area of expertise?
We specialize in the isolation, cultivation, and storage of adipose-derived and urine-derived stem cells, as well as immune cells, under GMP standards for regenerative recovery goals.
What are EHL BIO’s laboratory safety standards?
We utilize Class 100 laboratories and hold GMP certification from the Korean MFDS.
What are the goals for recovery and quality of life after service?
The main goal is to restore and promote the quality of life of the recipient. Every cell lot undergoes rigorous quality control for purity and viability to ensure they meet the standards defined in the care plan, according to EHL team evaluations.
Related conditions
Based on EHL BIO information: EHL BIO · EHL BIO · EHL BIO · EHL BIO. Each care plan follows an individual EHL assessment.
